ICCC
ImmuCell Corporation
NASDAQ: ICCC · HEALTHCARE · BIOTECHNOLOGY
$8.44
+1.08% today
Updated 2026-04-29
Market cap
$74.64M
P/E ratio
—
P/S ratio
2.70x
EPS (TTM)
$-0.12
Dividend yield
—
52W range
$5 – $8
Volume
0.0M
ImmuCell Corporation (ICCC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
-1.6%
Most recent quarter
EPS YoY growth
-646.7%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-6.3%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-11.9%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-04 | $-0.31 | — | $6.40 | $6.35 | -0.8% |
| 2025-11-13 | $-0.02 | — | $6.13 | $5.40 | -11.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | — | $-0.31 | — | $7.63M | -1.6% |
| 2025-09-30 | — | $-0.02 | — | $5.51M | -8.4% |
| 2025-06-30 | — | $0.06 | — | $6.44M | +17.8% |
| 2025-03-31 | — | $0.16 | — | $8.07M | +11.2% |
| 2024-12-31 | — | $0.06 | — | $7.75M | +52.1% |
| 2024-09-30 | — | $-0.09 | — | $6.01M | +11.4% |
| 2024-06-30 | — | $-0.20 | — | $5.47M | +54.9% |
| 2024-03-31 | — | $-0.06 | — | $7.26M | +110.6% |
| 2023-12-31 | — | $-0.15 | — | $5.10M | — |
| 2023-09-30 | — | $-0.12 | — | $5.40M | — |
| 2023-06-30 | — | $0.18 | — | $3.53M | — |
| 2023-03-31 | — | $-0.30 | — | $3.45M | — |
Frequently asked questions
Has ImmuCell Corporation beaten earnings estimates?
ImmuCell Corporation has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports.
How does ICCC stock react to earnings?
ICCC stock has moved an average of -6.3% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is ImmuCell Corporation's revenue growth rate?
ImmuCell Corporation reported year-over-year revenue growth of -1.6% in its most recent quarter, with EPS growing -646.7% year-over-year.